Vaxcyte, Inc. (PCVX)
PCVXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$67.53
+3.64 (+5.70%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $10.69bn
- P/E
- –
- EPS, last 4 quarters
- $-8.06
- Dividend yield
- –
- Day range
- –
- 52-week range
- $40.14 to $90.75
- Average volume
- 2.43m
- Previous close
- $63.89
Analysts
9 coveringBuy8 buy, 1 hold, 0 sell
Targets a year out average $114.11, +69.0% from here
Earnings
next estimate $-1.94Next report
Dec 2025
-23.3%
Mar 2026
-23.7%
Jun 2026
-34.0%
Sep 2026
-8.2%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$274.28m | -$345.85m | -$302.78m | -$308.27m |
| Net income | -$246.51m | -$320.62m | -$284.30m | -$297.06m |
News
8 latest- Vaxcyte, Inc. Reports Third Quarter 2026 Financial Results and VAX-31 Clinical ProgressFintel · 5 days ago
- Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?Zacks · Oct 30, 2026
- Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances RTTNews · Oct 16, 2026
- Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a BetZacks · Oct 14, 2026
- Interesting PCVX Put And Call Options For July 2027BNK Invest · Oct 12, 2026
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data RTTNews · Oct 9, 2026
- Stocks Finish Higher on Lower Bond Yields and Earnings OptimismBarchart · Oct 7, 2026
- Vaxcyte Prices Offerings Of Stock, Warrants, Convertible Notes To Raise Approx. $1 Bln RTTNews · Oct 7, 2026
The company
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, has generated positive Phase 2 clinical results in both adults and infants and is designed to cover more serotypes than any PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- vaxcyte.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.